Sponsor Pipeline

Liquidia Technologies, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
2
Recruiting
3
Phase 3
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-12 NCT07759804 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension… Phase 4 Not Yet Recruiting
2026-08-05 NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have… Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 4
1
Phase 3
3
Phase 2
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07759804 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension… Pulmonary Arterial Hypertension (PAH) Not Yet Recruiting
Phase 3
NCT07285655 A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD Pulmonary Hypertension Due to Lung Disease (Disorder) Recruiting
NCT03992755 Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry… Primary Pulmonary Hypertension Active, Not Recruiting
NCT04691154 A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or… Pulmonary Arterial Hypertension Active, Not Recruiting
Phase 2
NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have… Raynaud's Phenomenon Secondary to Systemic Sclerosis Not Yet Recruiting
Not specified
NCT06129240 An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry… Pulmonary Hypertension Recruiting
Disease Areas
Get alerts when Liquidia Technologies, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free